Working… Menu
Trial record 1 of 2 for:    servier | ASD
Previous Study | Return to List | Next Study

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03715153
Recruitment Status : Active, not recruiting
First Posted : October 23, 2018
Last Update Posted : January 20, 2021
ADIR, a Servier Group company
Information provided by (Responsible Party):
Servier ( Institut de Recherches Internationales Servier )

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 15, 2021
Estimated Study Completion Date : September 20, 2022